Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.

被引：1
|
作者：
Grivas, Petros
Laliberte, Francois
Doleh, Yunes
O'Connor, Cristi
Duh, Mei Sheng
Shenolikar, Rahul
机构：
[1] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[2] Grp Anal Ltee, Montreal, PQ, Canada
[3] AstraZeneca, Gaithersburg, MD USA
[4] Anal Grp Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
363
引用
收藏
页数：1
相关论文
共 50 条
  • [21] 'FLARE' of tumor marker in advanced gastric cancer treated with first-line systemic therapy
    Zhang, Fangyuan
    Zhai, Menglan
    Yang, Jinru
    Zhao, Lei
    Lin, Zhenyu
    Wang, Jing
    Zhang, Tao
    Yu, Dandan
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [22] Prognostic impact of first-line (1L) chemotherapy cycles in patients with metastatic urothelial carcinoma receiving avelumab 1L maintenance.
    Katayama, Satoshi
    Kawada, Tatsuhi
    Kobayashi, Keita
    Watanabe, Ryuta
    Tohi, Yoichiro
    Yamamoto, Shinkuro
    Takamoto, Atsushi
    Shimizu, Ryutaro
    Daizumoto, Kei
    Nagami, Taichi
    Wada, Koichiro
    Miura, Noriyoshi
    Morizane, Shuichi
    Furukawa, Junya
    Inoue, Keiji
    Sugimoto, Mikio
    Shiraishi, Koji
    Araki, Motoo
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [23] Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden
    Bellmunt, Joaquim
    Powles, Thomas
    Park, Se Hoon
    Voog, Eric
    Valderrama, Begona Perez
    Gurney, Howard
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Sternberg, Cora N.
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel P.
    Duran, Miguel A. Climent
    Tyroller, Karin
    Hoffman, Jason
    Jacob, Natalia
    Grivas, Petros
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Prevalence of PD-L1 expression in first-line (1L) locally advanced/unresectable or metastatic urothelial carcinoma (UC).
    Grivas, Petros
    Morgans, Alicia K.
    Lotan, Yair
    Gregg, Jeffrey P.
    Geynisman, Daniel M.
    Friedlander, Terence W.
    Agarwal, Piyush K.
    Tesic-Schnell, Marija
    Bernstein, Andrew
    Makari, Doris
    Meeks, Joshua J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [25] A retrospective study of vascular thromboembolic events (VaTEs) in patients receiving first line treatment for advanced urothelial cancer (AUC)
    Dimitriadis, I.
    Tsironis, G.
    Tzannis, K.
    Koutsoukos, K.
    Kostouros, E.
    Liontos, M.
    Lykka, M.
    Trajce, E.
    Nikolopoulos, K.
    Sfika, A.
    Kafantari, E.
    Zagouri, F.
    Matsouka, C.
    Dimopoulos, M. A.
    Bamias, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S514 - S514
  • [26] Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy.
    de Kouchkovsky, Ivan
    Moradpour, Moein
    Zhang, Li
    Tuchayi, Abuzar Moradi
    Zhu, Xiaolin
    Juarez, Roxanna
    Kwon, Daniel
    Koshkin, Vadim S.
    Chou, Jonathan
    Friedlander, Terence W.
    Small, Eric J.
    Aggarwal, Rahul Raj
    Hope, Thomas A.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [27] Treatment-Related Adverse Events in Patients with Advanced NSCLC Treated with First-Line Atezolizumab Chemoimmunotherapy
    Swarup, S.
    Thein, K.
    Sultan, A.
    Jahan, N.
    Quirch, M.
    Meda, S.
    Htut, T.
    Adhikari, N.
    Hlaing, P.
    Dash, A.
    Tun, A.
    Rehman, S.
    Hardwicke, F.
    Tijani, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S390 - S390
  • [28] Real-world safety of first-line (1L) therapies for locally advanced or metastatic urothelial cancer (la/mUC) in the US.
    Nizam, Amanda
    Kearney, Mairead
    Morris, Valerie A.
    Mahmoudpour, Seyed Hamidreza
    Lobo, Carroline
    Hoffman, Jason
    Iliev, Ilian
    Yerram, Prakirthi
    Guinter, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [29] Analysis of therapy attrition and changes in outcomes over time for patients (pts) with advanced urothelial cancer (aUC) treated at an academic center.
    Reyes, Kevin R.
    Jindal, Tanya
    Deshmukh, Prianka
    Zhu, Xiaolin
    Ding, Chien-Kuang Cornelia
    Wong, Anthony C.
    Chu, Carissa E.
    Porten, Sima P.
    Chou, Jonathan
    Friedlander, Terence W.
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 590 - 590
  • [30] Adverse event (AE) burden of nivolumab-based immunooncology (IO) therapy with/without chemotherapy (chemo) for first-line (1L) advanced non-small cell lung cancer (aNSCLC)
    Schwartzberg, L.
    Wu, A.
    Hartman, J.
    Wang, T.
    Yin, X.
    Chen, J.
    Betts, K. A.
    Lubinga, S. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1069 - S1070
12345